Page 151 - CombinedTest_Neat
P. 151

Site Performance Summary:
                                     Mercy Health Youngstown's supply expense is under budget $2.52M
                                     (8.4%) after adjustments booked per the recent supply and pharmacy
                                     inventory counts.  Excluding this adjustment expense is over budget by
                                     $217K (1.5%) despite gross revenue coming in under budget by 2.0M (1%).
                                     The primary driver of this variance was Medical Surgical supplies, which
                                     came in $440K, 10% under budget.  Drugs exceeded budget by $365K (7%)
                                     on higher chemotherapy/infusion volume as well as thye new Outpatient
                                     Pharmacy and 340B program ramp-up at Boardman.  Overall surgical
                                     volume was down 128 cases (7%), with inpatient procedures coming in
                                     16% under budget.  Implants exceeded budget by $351K (13%), with the
                                     main driver being TAVR expense at St. Elizabeth.  The decrease in surgical
                                     volume resulted in Medical Surgical supplies coming in $440K (6.8%) under
                                     budget.    Implant Other exceeded budget by $164K, mainly driven by
                                     CardioMEMS ($39K) and Occluder PFO expense ($20K) at St. Elizabeth.
                                     Orthopedic joint implants exceeded budget by $90K (20%) on a mix of
                                     increased revision and total shoulder volume (14 cases vs. 6 PY) vs. lower
                                     than expected primary implants (91 cases vs. 75 PY).


               Youngstown Leader's Summary
                 Key Challenges: 2-3 key contributors for each expense subaccount
                                     Overall low OR volume (18% under budget) was main driver of the facility-
                                     wide positive expense variance at SEYH (OR down $250K, 35%).

                                     MedSurg expense decreased in-step with soft surgical volumes for the
                       Med/Surg      period.





                                     Oncology and infusion services continues to drive Pharma expense with
                                     increases noted for all three acute care sites.
                          Rx



                                     Orthopedic implants exceeded budget for the region by $90K (20%) on
                                     fewer primary procedures vs. increase in revisions.
                                     Strong Cath Lab volume at St. Elizabeth is driving revenue and improved
                                     contribution to margin based on facility's use of Abbott DES.
                        Implants

                                     Implant other is a considerable bucket that requires improved surveillance
                                     and reporting in order to review and understand volumes.

                                     Red Cross blood expese came in under budget by $99K.  Blood is
                                     transferred from St. Elizabeth to other MHY acute care facilities by Red
                                     Cross - the vendor was behind in "truing-up" expense, credits have been
                                     applied to SEYH, varying impact at SEBH and SJWH.  This process is to be
                                     reviewed in January.
                      Other Expenses
                                     Freight came in $81K under budget due to $52K in Medline LUM fees
                                     reclassed from freight to purchase services at Boardman, as well as a $72K
                                     Omnicell freight charge credit at SEBH and SJWH.



                 Actions Taken/Planned:
                      Volume Data
                       Alt Sourcing
                     Capital Avoidance
   146   147   148   149   150   151